Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (June 2022)
26 slides from Noxopharm's investor presentation, Jun 7, 2022
Slide 1: Noxopharm Corporate Presentation
NOXOPHARM CORPORATE PRESENTATION For personal use only Sydney 7 June 2022: Australian biotech Noxopharm Limited (ASX:NOX) is pleased to provide a corporate slide deck ahead of a series of non-deal investor meetings. The release is accompanied by a recorded presentation by the recently appointed CEO
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Noxopharm Limited: Delivering Science. Transforming Lives.
For personal use only NOXOPHARM LIMITED Delivering Science. Transforming Lives. NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for secu
Slide 5: Noxopharm: Committed to developing life-saving therapies
For personal use only Noxopharm Committed to developing life-saving therapies
Slide 6: Noxopharm Overview
Noxopharm Overview For personal use only • Noxopharm is an innovative biotechnology company with a science driven strategy to advance the most promising life-saving therapies for patients with cancer or inflammatory diseases • It has grown to have three separate drug development programs: o Lead cli
Slide 7: Highly Qualified and Experienced Management Team
Highly Qualified and Chief Executive Officer and Managing Director Experienced Dr Gisela Mautner MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), MAICD • Over 30 years’ experience in healthcare across four continents with leadership roles in For personal use only Global Pharmaceuticals includin
Slide 8: The Noxopharm Network
The Noxopharm Network For personal use only Hudson NIH NCI Goethe Weill Cornell Institute of National Institutes National Cancer Universität Medicine Medical Research of Health Institute Frankfurt Am Main New York Melbourne USA USA Australian The University of University of New University of Univers
Slide 9: Value Cascade
Value Cascade For personal use only Clinical Trials Noxopharm’s science driven strategy is to advance the most In vivo Efficacy promising life-saving therapies through the discovery, preclinical Formulation Studies and clinical phases. Its focus is on adding value to Toxicology its assets at each st
Slide 10: The Noxopharm Business Model
The Noxopharm Business Model Out-licensing For personal use only Upfront payment Proprietary and in-licenced Milestones drugs are advanced through Royalties drug development, with a view to out-licensing them at key value inflection points. Clinical Pre-Clinical Out-licensing Upfront payment Milesto
Slide 11: Three Separate Therapy Development Programs
Three Separate Therapy Development Programs For personal use only Lead Candidate Innovative Technology Platforms Veyonda® ChromaTM SofraTM Clinical Phase 1 / 2 Trials Preclinical Studies NOXOPHARM (ASX:NOX) - June 2022 9
Slide 12: Veyonda Combination Therapy Programs
Veyonda® Combination Therapy Programs For personal use only DARRT CEP IONIC (IIT*) External Beam Radiation Chemotherapy Immuno-oncology Therapy Working with top ranked cancer centres in the USA * IIT – investigator initiated trial NOXOPHARM (ASX:NOX) - June 2022 10
Slide 13: Veyonda Clinical Development
Veyonda® Clinical Development For personal use only Program Combination Indication Phase 1 Phase 2 Status DARRT-1 DARRT-1 manuscript in + Radiation DARRT-2 Active DARRT Prostate Cancer preparation; DARRT-2 Therapy Completed recruiting Results published Multiple Tumours CEP-1 Completed in CTR 2021 CE
Slide 14: Regulatory Engagement for Veyonda
Regulatory Engagement for Veyonda® For personal use only Orphan Drug Designation (ODD) Highly Valuable ODD Benefits • US Food and Drug Administration (FDA) granted ODD to Veyonda for soft ODD encourages the development of safe and effective tissue sarcoma – early 2022 treatments of rare diseases aff
Slide 15: Innovation is Needed in Prostate Cancer
Innovation is Needed in Prostate Cancer For personal use only Prostate cancer is one of the most common cancers in men. In 2022 in the US, there will be an estimated 268,490 new prostate Poor outlook in advanced cases1 cancer cases and 34,500 deaths2 • Current treatments slow or shrink an advanced p
Slide 16: Unmet Medical Need in Sarcoma
Unmet Medical Need in Sarcoma For personal use only Soft tissue sarcomas are rare but often fatal cancers. In the US each year, up to 16,000 new sarcoma cases are diagnosed, Limited treatment options and up to 6,000 related deaths are recorded1 • Surgery, chemotherapy and/or radiotherapy are all exi
Slide 17: Scientific Validation of Trial Results
Scientific Validation of Trial Results For personal use only Peer-reviewed publications of key results validate the science behind Noxopharm’s drug candidates NOXOPHARM (ASX:NOX) - June 2022 15
Slide 18: Innovative Technology Platforms – Preclinical Stage
Innovative Technology Platforms – Preclinical Stage For personal use only Program Discovery Screening Preclinical Collaborators CRO-XX Pancreatic Cancer UNSW TBK1 inhibitors Cancer/Inflammation Hudson Institute of Medical Research ChromaTM Undisclosed Cancer Macquarie University Hudson Institute of
Slide 19: Chroma: Pancreatic ductal adenocarcinoma (PDAC)
ChromaTM Pancreatic ductal adenocarcinoma (PDAC) For personal use only • PDAC is the fourth leading cause of cancer- related deaths in developed countries • 5-year survival rate of 8% from diagnosis1, ✓ Shared specific and novel bioactive properties minimal improvements in the past four decades ✓ Gr
Slide 20: Novel 'Dual-Cell' Therapy for Pancreatic Cancer
Novel ‘Dual-Cell’ Therapy for Pancreatic Cancer For personal use only Tumour Growth Treated with CRO-XX Tumour Reduction Tumour Scar Tissue Cells of the Current Immune Cell Immune System Drugs Penetration ‘Dual-Cell’ Therapy of and Opening the Gates to Growing Tumour Shielded CRO-XX through Immune C
Slide 21: Sofra
SofraTM For personal use only Nature Proprietary Technology RNA / DNA Oligonucleotides Chemically engineered oligonucleotides • Over 200 synthetic sequences • Composition of Matter patents • Targeting inflammatory and autoimmune diseases • Novel treatment approach First-in-class drug candidates NOXO
Slide 22: Financial Summary
Financial Summary (ASX:NOX) For personal use only Capital Structure Cash Position Share price1 $0.315 Current Cash Holdings4 $18.1M Shares on issue 292M Average Cash burn/mth $1.9M Market Capitalisation1 $92M Est R&D rebate for 2021/225 $5-6M Net capital raised2 $63.8M Govt grants/rebates received3
Slide 23: 2022 Catalysts
2022 Catalysts For personal use only IONIC DARRT-2 Safety & SofraTM Patent Safety Interim Preclinical Portfolio Results Efficacy Results Growth Signals ChromaTM CEP-2 Pancreatic Regulatory Safety Cancer Engagement Results Preclinical Results NOXOPHARM (ASX:NOX) - June 2022 21
Slide 24: Integrating ESG into Everyday Practice
Integrating Environment, Social and Governance (ESG) into Everyday Practice For personal use only NOXOPHARM (ASX:NOX) - June 2022 22
Slide 25: Investment Highlights
Investment Highlights For personal use only Science-driven Expert Three exciting strategy to management drug Multiple clinical Well funded advance drugs team & network development data catalysts with cash to key value of leading programs ahead, plus runway beyond inflection points, medical focused o
Slide 26: Noxopharm Limited: Delivering Science. Transforming Lives.
For personal use only NOXOPHARM LIMITED Delivering Science. Transforming Lives. www.noxopharm.com NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.